CAR T-cell Therapy
Immunotherapy with TIL for Cancer
This trial is testing a new experimental therapy to see if it can cause tumors to shrink in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. The therapy involves taking white blood cells from patients' tumors, growing them in the laboratory, and then giving the cells back to the patient.
Popular Filters
Trials for GBM Patients
ATR Kinase Inhibitor
Adavosertib + Radiation + Temozolomide for Glioblastoma
This trial tests the safety and best dose of adavosertib combined with radiation and temozolomide for treating glioblastoma. Adavosertib blocks enzymes needed for tumor growth, while radiation and temozolomide kill cancer cells and stop them from growing. The study aims to find the most effective dose and understand how well this combination works for patients with newly diagnosed or recurrent glioblastoma.
Trials for Solid Tumors Patients
ATR Kinase Inhibitor
Adavosertib + Radiation + Temozolomide for Glioblastoma
This trial tests the safety and best dose of adavosertib combined with radiation and temozolomide for treating glioblastoma. Adavosertib blocks enzymes needed for tumor growth, while radiation and temozolomide kill cancer cells and stop them from growing. The study aims to find the most effective dose and understand how well this combination works for patients with newly diagnosed or recurrent glioblastoma.
Cancer Vaccine
Vaccine Therapy + Temozolomide for Glioblastoma
This trial studies how well a special vaccine works with a common chemotherapy drug in treating patients with recently found brain cancer. The vaccine helps the immune system fight the cancer, while the chemotherapy attacks the cancer cells directly.
Trials for MET Positive Patients
Cancer Vaccine
Personalized Cancer Vaccine + RT + Pembrolizumab for Glioblastoma
This trial is studying a new type of vaccine as a possible treatment for patients with glioblastoma. It is evaluating the safety of the vaccine and finding the right dose to use.
Alkylating agents
Pembrolizumab + Temozolomide + TTFields for Glioblastoma
This trial is testing whether adding pembrolizumab to the standard treatment for glioblastoma (surgery, radiation, and chemotherapy) can help patients live longer without their disease progressing.
Monoclonal Antibodies
Anti-Tim-3 + Anti-PD-1 + SRS for Glioblastoma
This trial studies a combination of precise radiation therapy and immune-boosting drugs to treat patients with recurring brain cancer. The goal is to directly target the tumor and enhance the body's immune response against cancer cells.
IDO1 Inhibitor
Immunotherapy + Targeted Therapy + Radiation for Glioblastoma
This trial is testing a combination of immunotherapy and targeted therapy with radiation therapy, with or without chemotherapy, to see if it is more effective than standard radiation therapy with or without chemotherapy in treating patients with newly diagnosed glioblastoma.
Chemotherapy
OKN-007 + Temozolomide for Recurrent Brain Cancer
This trial is testing a new drug called OKN-007 combined with a chemotherapy drug, temozolomide, in patients whose brain cancer has returned after standard treatments. OKN-007 may help reduce tumor growth and make the chemotherapy more effective. Temozolomide is effective in treating malignant brain tumors.
Trials for MGMT Positive Patients
Alkylating agent
OKN-007 + Temozolomide for Glioblastoma
This trial is testing if adding the drug OKN-007 to the standard treatment with Temozolomide and radiotherapy can help patients with malignant Glioblastoma, especially those whose cancer has gotten worse after initial treatment. Temozolomide has become a cornerstone in the treatment of glioblastoma, often used in combination with radiotherapy.
PARP Inhibitor
Niraparib + Optune for Glioblastoma
This trial tests niraparib and TTFields in patients with recurrent glioblastoma. The electric fields weaken the cancer cells, and the drug stops them from fixing themselves, leading to cell death. Tumor-Treating Fields (TTFields) is a noninvasive cancer treatment that uses low-intensity alternating electric fields to disrupt cell division and has been FDA-approved for glioblastoma.
Trials With No Placebo
ATR Kinase Inhibitor
Adavosertib + Radiation + Temozolomide for Glioblastoma
This trial tests the safety and best dose of adavosertib combined with radiation and temozolomide for treating glioblastoma. Adavosertib blocks enzymes needed for tumor growth, while radiation and temozolomide kill cancer cells and stop them from growing. The study aims to find the most effective dose and understand how well this combination works for patients with newly diagnosed or recurrent glioblastoma.
View More Related Trials
Frequently Asked Questions
Introduction to gbm
What are the top hospitals conducting gbm research?
When it comes to cutting-edge clinical trials for glioblastoma (gbm), several renowned hospitals are leading the charge. One such institution is the Dana-Farber Cancer Institute in Boston, which currently has 17 active gbm trials underway. Glioblastoma, a highly aggressive and deadly form of brain cancer, poses significant challenges for patients and researchers alike. Likewise, Washington University School of Medicine in Saint Louis is also making strides with 14 ongoing gbm trials of their own. Memorial Sloan Kettering Cancer Center in New york follows closely behind with 13 active gbm trials. These institutions bring together top medical professionals and scientists who work tirelessly to find new treatment options and improve outcomes for those affected by this devastating disease.
Meanwhile, Johns Hopkins University/Sidney Kimmel Cancer Center in Baltimore joins this league with ten ongoing clinical trials specifically focused on glioblastoma research. Last but not least, the Moffitt Cancer Center located in Tampa contributes significantly to the fight against gbm as well; they presently have nine active clinical trials dedicated solely to finding innovative solutions for this challenging condition.
While these hospitals might not yet have any completed or all-time recorded gbm trials under their belts, their commitment to pursuing groundbreaking research offers hope to patients worldwide. By pushing boundaries and exploring novel approaches through these ongoing studies, these institutions play an integral role in advancing our understanding and management of glioblastoma—a crucial step toward improved treatments and ultimately a potential cure that could transform countless lives impacted by this formidable disease.
Which are the best cities for gbm clinical trials?
When it comes to gbm clinical trials, several cities emerge as leading hubs for research and development. Boston, Massachusetts leads the pack with 56 active trials investigating treatments like Ipilimumab, Adavosertib, and others. New york, New York closely follows with 48 ongoing studies focusing on INO-5401, VAL-083, and more. Los Angeles, California is another prominent city in the field with 44 active trials exploring Veliparib and other interventions. Saint Louis, Missouri and Baltimore Maryland also contribute significantly to gbm clinical trials with 27 and 26 active studies respectively. These cities provide individuals battling glioblastoma multiforme access to cutting-edge research that may lead to groundbreaking advancements in treatment options.
Which are the top treatments for gbm being explored in clinical trials?
Glioblastoma multiforme (GBM) remains a challenging disease to treat, but ongoing clinical trials offer hope for patients. Among the top treatments being explored are:
- Temozolomide: Currently involved in 8 active GBM trials and has been widely studied with over 260 all-time trials.
- Bevacizumab: Showing promise in its role as an anti-angiogenic therapy, it is being investigated in 7 active GBM trials and has accumulated over 150 all-time studies.
- Lomustine: With involvement in 5 active GBM trials and over 130 all-time studies, this alkylating agent continues to be explored for its potential benefits. These three treatments represent some of the leading avenues of research that could potentially revolutionize the management of GBM.
What are the most recent clinical trials for gbm?
Recent clinical trials have brought new hope for patients with glioblastoma (gbm), a challenging form of brain cancer. Among these trials, NanO2TM in Phase 2 has shown promise as a potential treatment option. Another study in Phase 3 investigated the combination of radiation therapy (RT) with temozolomide (TMZ) and enzastaurin (ENZ), as well as ENZ alone or TMZ and ENZ, offering potential advancements in gbm treatment approaches. Furthermore, an innovative trial using human CMV pp65-LAMP mRNA-pulsed autologous dendritic cells aims to harness the power of immunotherapy against gbm. These recent developments offer renewed optimism for patients fighting this aggressive disease.
What gbm clinical trials were recently completed?
Recently completed clinical trials for glioblastoma (GBM), a highly aggressive form of brain cancer, have made significant strides in advancing treatment options. One notable trial focused on the investigation of Uproleselan, led by Washington University School of Medicine and concluded in October 2021. Another groundbreaking study sponsored by the National Cancer Institute examined the efficacy of mRNA-1273 and finished its research phase in September 2021. Lastly, AgenTus Therapeutics successfully completed their agenT-797 trial in January 2021. These achievements highlight the dedication of researchers to combat GBM and provide hope for patients grappling with this devastating disease.